Overview
Minimal pigment oculocutaneous albinism type 1 (also called OCA1-MP or OCA type 1 minimal pigment) is a rare inherited condition that affects the coloring of the skin, hair, and eyes. It is a subtype of oculocutaneous albinism type 1, which is caused by changes in the TYR gene responsible for producing the enzyme tyrosinase. This enzyme is essential for making melanin, the pigment that gives color to skin, hair, and eyes. In this form, people are born with very little or no pigment, similar to the most severe form (OCA1A), but over time they may develop a very small amount of pigment, particularly in the hair and eyes. Hair may become slightly yellow or light blonde, and the irises may develop a small amount of blue or light color as the person ages. The most significant effects of this condition are on the eyes. People with minimal pigment OCA1 typically have reduced visual acuity (blurry vision), nystagmus (involuntary back-and-forth eye movements), sensitivity to bright light (photophobia), and abnormal routing of the optic nerves. Strabismus (crossed eyes) is also common. The skin remains very fair and is highly susceptible to sunburn and skin cancer due to the near-absence of protective melanin. There is currently no cure for this condition. Treatment focuses on protecting the skin from sun damage, correcting vision problems with glasses or low-vision aids, and regular monitoring by eye and skin specialists. With proper care and sun protection, individuals with this condition can lead full and active lives.
Also known as:
Key symptoms:
Very light or white skin at birthWhite or very light blonde hair that may develop slight yellow tint over timeLight blue or gray eyes with possible slight pigment developmentBlurry vision or reduced visual sharpnessInvoluntary eye movements (nystagmus)Sensitivity to bright light (photophobia)Crossed eyes (strabismus)Severe sunburn with minimal sun exposureIncreased risk of skin cancerDifficulty seeing fine detailsReduced depth perceptionFoveal hypoplasia (underdeveloped central part of the retina)Translucent or very light-colored irises
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Minimal pigment oculocutaneous albinism type 1.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Minimal pigment oculocutaneous albinism type 1 at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Minimal pigment oculocutaneous albinism type 1.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Minimal pigment oculocutaneous albinism type 1.
Community
No community posts yet. Be the first to share your experience with Minimal pigment oculocutaneous albinism type 1.
Start the conversation →Latest news about Minimal pigment oculocutaneous albinism type 1
No recent news articles for Minimal pigment oculocutaneous albinism type 1.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What is my child's current level of vision, and what aids or devices would help the most?,How often should we schedule eye exams and skin cancer screenings?,What specific sun protection measures do you recommend for our daily routine?,Are there any clinical trials or new treatments being studied for this type of albinism?,What school accommodations should we request for our child's vision needs?,Should other family members be tested to see if they carry the gene change?,What signs of skin cancer should we watch for, and when should we seek urgent care?
Common questions about Minimal pigment oculocutaneous albinism type 1
What is Minimal pigment oculocutaneous albinism type 1?
Minimal pigment oculocutaneous albinism type 1 (also called OCA1-MP or OCA type 1 minimal pigment) is a rare inherited condition that affects the coloring of the skin, hair, and eyes. It is a subtype of oculocutaneous albinism type 1, which is caused by changes in the TYR gene responsible for producing the enzyme tyrosinase. This enzyme is essential for making melanin, the pigment that gives color to skin, hair, and eyes. In this form, people are born with very little or no pigment, similar to the most severe form (OCA1A), but over time they may develop a very small amount of pigment, particul
How is Minimal pigment oculocutaneous albinism type 1 inherited?
Minimal pigment oculocutaneous albinism type 1 follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Minimal pigment oculocutaneous albinism type 1 typically begin?
Typical onset of Minimal pigment oculocutaneous albinism type 1 is neonatal. Age of onset can vary across affected individuals.